Nelfinavir
It is an inhibitor of the human immunodeficiency virus (HIV) protease.Inhibition of the viral protease prevents cleavage of the gag-pol polyprotein resulting in the production of immature, non-infectious virus.It is indicated for the treatment of HIV infection when antiretroviral therapy is warranted.
Adults : The recommended dose is 750 mg (three 250 mg tablets) three times daily. Nelfinavir mesylate should be taken with a meal or light snack. Pediatric : The recommended oral dose of nelfinavir mesylate for pediatric patients 2 to 13 years of age is 20-30 mg/kg per dose, three times daily with a meal or a light snack.
It is contraindicated in patients with clinically significant hypersensitivity to any of its components.
Nelfinavir is principally metabolized by the liver. Therefore, caution should be exercised when administering this drug to patients with hepatic impairment. Lactation: It is not known whether nelfinavir is excreted in human milk.
Back pain, fever, headache, anorexia, dyspepsia, gastrointestinal bleeding, hepatitis, anemia, leukopenia and thrombocytopenia, anxiety, depression, dizziness, sleep disorder, suicide ideation, dyspnea, pharyngitis, rhinitis, dermatitis, eye disorder, sexual dysfunction and urine abnormality.
The drugs which shouldnot be co-administered with Nelfinavir Mesylate are Amiodarone, quinidine, astemizole, terfenadine, ergot derivatives, rifampin, midazole, triazolam, cisapride
